Loading
A phase 3 trial of Vusolimogene oderparepvec, Nivolumab, Relatlimab + nivolumab and Pembrolizumab in Advanced melanoma, run by Replimune, Inc., now recruiting.
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] is a phase 3 interventional study registered as NCT06264180 by Replimune, Inc., with 400 participants planned, started 2024-07-11 and due to reach its primary completion in 2030-09-30. Interventions recorded: Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab, Pembrolizumab, Single-agent chemotherapy. Conditions recorded: Advanced Melanoma.
Linked to the drug Vusolimogene oderparepvec because the registry names it among its interventions and Advanced melanoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Vusolimogene oderparepvec, Pembrolizumab and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Pembrolizumab and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab and the tag pipeline.
Shares Replimune and the tag pipeline.
Shares Nivolumab, Pembrolizumab and the tag pipeline.
Shares Nivolumab, Pembrolizumab and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/